Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

940.00USD
--
Change (% chg)

-- (--)
Prev Close
$940.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22
52-wk High
$1,231.90
52-wk Low
$788.70

Latest Key Developments (Source: Significant Developments)

Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer
Friday, 21 Apr 2017 02:06pm EDT 

April 21 (Reuters) - Bristol-Myers Squibb Co : :Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.CHMP opinion based on tumor response rate and duration of response demonstrated in phase 2 checkmate -275 trial.  Full Article

Bristol-Myers,Nordic Bioscience announce collaboration for fibrosis biomarker technology
Monday, 17 Apr 2017 06:59am EDT 

April 17 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb and Nordic Bioscience announce collaboration for fibrosis biomarker technology.Collaboration to develop translational biomarkers for fibrotic diseases, including non-alcoholic steatohepatitis.  Full Article

Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb
Thursday, 13 Apr 2017 07:00am EDT 

Biogen Inc : Biogen Inc - under agreement, biogen will receive worldwide rights to BMS-986168 . Biogen Inc - Biogen will be responsible for full development and global commercialization of bms-986168 in ad and psp . Biogen Inc - to assume all remaining obligations to former stockholders of Ipierian, Inc related to Bristol-Myers Squibb's acquisition of company in 2014 . Biogen Inc - may pay up to $550 million in remaining milestones plus royalties including a near term $60 million milestone .Biogen Inc - announced an agreement to exclusively license BMS-986168 from Bristol-Myers Squibb.  Full Article

Bristol-Myers and Apexigen announce clinical collaboration to evaluate Opdivo in combination with APX005M in advanced solid tumors
Tuesday, 11 Apr 2017 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb and Apexigen, Inc. announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with APX005M in advanced solid tumors . Bristol-Myers - Study to evaluate potential of APX005M + Opdivo to activate antigen-presenting cells in tumor microenvironment to show anti-tumor activity . Bristol-Myers Squibb- Study to enroll second-line metastatic non-small cell lung cancer patients who have failed prior chemotherapy .Study to also enroll metastatic melanoma patients who have failed prior I-O therapy.  Full Article

FDA accepts for priority review Bristol-Myers' application for Opdivo in previously treated metastatic colorectal cancer
Tuesday, 4 Apr 2017 04:15pm EDT 

Bristol-myers Squibb Co : U.S. Food and Drug Administration accepts for priority review Bristol-Myers Squibb's application for Opdivo (nivolumab) in previously treated DMMR or MSI-H metastatic colorectal cancer .Bristol-Myers Squibb Co - FDA granted application priority review, and FDA action date is August 2, 2017.  Full Article

Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo
Friday, 24 Mar 2017 08:31am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb receives positive chmp opinion recommending opdivo (nivolumab) for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy . Bristol-Myers Squibb Co - positive opinion based on overall survival benefit demonstrated in phase 3 checkmate -141 trial . Bristol-Myers Squibb Co- safety profile of opdivo in checkmate -141 was consistent with prior studies in other tumors .Bristol-Myers Squibb - CHMP recommendation will now be reviewed by European Commission.  Full Article

Heat Biologics reports positive results from mid-stage lung cancer trial
Tuesday, 21 Mar 2017 07:00am EDT 

Heat Biologics Inc : Heat Biologics reports positive interim phase 2 lung cancer results in patients treated with hs-110 in combination with a checkpoint inhibitor . Immune responses to hs-110 were observed in all 5 patients that exhibited tumor reductions .No tumor reductions were observed in patients that did not mount an immune response to hs-110.  Full Article

Bristol-Myers Squibb, Cytomx Therapeutics extend worldwide collaboration
Monday, 20 Mar 2017 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb and Cytomx Therapeutics extend worldwide collaboration to discover Probody Therapeutics for the treatment of cancer and other diseases . Bristol-Myers Squibb Co - Cytomx to receive $200 million upfront payment . Bristol-Myers Squibb - Cytomx will also be eligible to receive up to $448 million in future development, regulatory,sales milestone payments for each collaboration target . Bristol-Myers Squibb Co - collaboration includes up to eight additional targets in oncology and other therapeutic areas .Bristol-Myers Squibb Co - Cytomx will grant Bristol-Myers Squibb exclusive worldwide rights to develop and commercialize Probody Therapeutics.  Full Article

Transgene SA says first results from Phase 2 trial could be expected from end of 2017
Monday, 13 Mar 2017 01:00pm EDT 

Transgene SA : First patient dosed in Phase 2 trial evaluating Transgene's TG4010 in combination with Opdivo(nivolumab) for 2nd line treatment of metastatic non-small cell lung cancer (NSCLC) .First results from Phase 2 trial could be expected from end of 2017.  Full Article

Heat Biologics Meets Efficacy Endpoint in Phase 1B Lung Cancer Trial
Monday, 13 Mar 2017 07:00am EDT 

Heat Biologics Inc : Heat biologics meets efficacy endpoint in its phase 1b lung cancer trial to progress to phase 2 . Data monitoring committee (dmc) determined that phase 1b safety endpoint was met . There do not appear to be additional toxicities seen in Hs-110/Nivolumab combination compared to existing data on nivolumab alone .5 out of 15 patients treated with Hs-110/Nivolumab combination had 20% or greater tumor reduction.  Full Article

More From Around the Web

Bristol-Myers NASH drug reduces liver fat in midstage study

Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.